Duality Biotherapeutics Inc Stock price
Is Duality Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.
Key metrics
Duality Biotherapeutics Inc Stock Analysis
Analyst Opinions
13 Analysts have issued a Duality Biotherapeutics Inc forecast:
Analyst Opinions
13 Analysts have issued a Duality Biotherapeutics Inc forecast:
Don't miss a Thing! We will send you all news about Duality Biotherapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Duality Biotherapeutics, Inc. operates as a clinical stage company. The company is headquartered in Shanghai, Shanghai and currently employs 231 full-time employees. The company went IPO on 2025-04-15. The firm is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The firm's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The firm's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The firm principally conducts its businesses in domestic and overseas markets.
| Head office | Cayman Islands |
| Employees | 231 |
| Website | www.dualitybiologics.com |


